Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Industry: Pharmaceutical Preparations Peers: Avidity Biosciences, Inc. Cogent Biosciences Inc Crinetics Pharmaceuticals Inc Emergent BioSolutions Inc Enanta Pharmaceuticals Inc Erasca Inc Forma Therapeutics Holdings, Inc. ImmunoGen, Inc. REGENXBIO Inc.